疾病预防控制中心:癌症死亡率正在下降
CDC: Cancer Death Rates Are Declining

CDC: Cancer Death Rates Are Declining

疾病预防控制中心:癌症死亡率正在下降

在美国和世界范围内,癌症仍然是导致死亡的主要原因之一。然而,美国疾病控制与预防中心(CDC)在其最新的年度报告中透露了一些好消息:从2001年到2017年,美国的癌症死亡率有所下降

特别是在2013年至2017年期间,全球癌症死亡的主要原因——肺癌的死亡率——男性每年下降4.8%,女性每年下降3.7%。总体而言,大多数癌症的死亡率以及所有人口群体的死亡率都有所下降。虽然这是一个好消息,但该报告也强调,需要采取更多措施来保持这一趋势。

归功于大型制药公司

近年来,数十家制药公司在抗癌斗争中做出了重大贡献。例如,制药巨头默克公司销售Keytruda,它现在被批准用于治疗小细胞肺癌、头颈癌和肝癌等多种癌症。Keytruda仍在被评估为一种治疗其他许多人的药物,并可能看到一些伟大的日子在未来:这一大片预计将成为世界上最畅销的药物在未来几年内。

百时美施贵宝(NYSE:BMY)也有一系列令人兴奋的癌症治疗产品,包括Opdivo等产品,Opdivo被批准用于黑色素瘤(皮肤癌)、肺癌、肾癌等。它还销售用于治疗多发性骨髓瘤的Revlimid。

Cancer continues to be one of the leading causes of death in the U.S. and worldwide. However, the Centers for Disease Control and Prevention (CDC) revealed some good news on that front in its latest annual report: Cancer death rates declined from 2001 to 2017 in the U.S.

In particular, between 2013 and 2017, the death rate for lung cancer -- the leading cause of cancer death globally -- decreased by 4.8% per year among men and by 3.7% per year among women. Overall, death rates declined for most forms of cancer and in all demographic groups. While this was excellent news, the report also emphasized that more needs to be done to keep that trend going.

Credit to big pharma

Dozens of drugmakers have made significant contributions in the fight against cancer in recent years. For instance, pharma giant Merck markets Keytruda, which is now approved as a treatment for small cell lung cancer, head and neck cancer, and liver cancer, among many others. Keytruda is still being evaluated as a treatment for many others, and will likely see some great days ahead: The blockbuster is projected to become the world's best-selling drug within the next few years.

Bristol Myers Squibb (NYSE:BMY) also has an exciting lineup of cancer treatments, including products such as Opdivo, which is approved for melanoma (skin cancer), lung cancer, kidney cancer, and others. It also markets Revlimid, which is used to treat multiple myeloma.

Cancer continues to be one of the leading causes of death in the U.S. and worldwide. However, the Centers for Disease Control and Prevention (CDC) revealed some good news on that front in its latest annual report: Cancer death rates declined from 2001 to 2017 in the U.S.

在美国和世界范围内,癌症仍然是导致死亡的主要原因之一。然而,美国疾病控制与预防中心(CDC)在其最新的年度报告中透露了一些好消息:从2001年到2017年,美国的癌症死亡率有所下降

In particular, between 2013 and 2017, the death rate for lung cancer -- the leading cause of cancer death globally -- decreased by 4.8% per year among men and by 3.7% per year among women. Overall, death rates declined for most forms of cancer and in all demographic groups. While this was excellent news, the report also emphasized that more needs to be done to keep that trend going.

特别是在2013年至2017年期间,全球癌症死亡的主要原因——肺癌的死亡率——男性每年下降4.8%,女性每年下降3.7%。总体而言,大多数癌症的死亡率以及所有人口群体的死亡率都有所下降。虽然这是一个好消息,但该报告也强调,需要采取更多措施来保持这一趋势。

Credit to big pharma

归功于大型制药公司

Dozens of drugmakers have made significant contributions in the fight against cancer in recent years. For instance, pharma giant Merck markets Keytruda, which is now approved as a treatment for small cell lung cancer, head and neck cancer, and liver cancer, among many others. Keytruda is still being evaluated as a treatment for many others, and will likely see some great days ahead: The blockbuster is projected to become the world's best-selling drug within the next few years.

近年来,数十家制药公司在抗癌斗争中做出了重大贡献。例如,制药巨头默克公司销售Keytruda,它现在被批准用于治疗小细胞肺癌、头颈癌和肝癌等多种癌症。Keytruda仍在被评估为一种治疗其他许多人的药物,并可能看到一些伟大的日子在未来:这一大片预计将成为世界上最畅销的药物在未来几年内。

Bristol Myers Squibb (NYSE:BMY) also has an exciting lineup of cancer treatments, including products such as Opdivo, which is approved for melanoma (skin cancer), lung cancer, kidney cancer, and others. It also markets Revlimid, which is used to treat multiple myeloma.

百时美施贵宝(NYSE:BMY)也有一系列令人兴奋的癌症治疗产品,包括Opdivo等产品,Opdivo被批准用于黑色素瘤(皮肤癌)、肺癌、肾癌等。它还销售用于治疗多发性骨髓瘤的Revlimid。